FKW 00GA

Drug Profile

FKW 00GA

Alternative Names: FKW00GA; TGW 00AA; TGW00AA HCl; TGWOOAA; TGWOOAA HCl

Latest Information Update: 08 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Unknown
  • Developer Fabre-Kramer Pharmaceuticals
  • Class Anxiolytics
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Generalised anxiety disorder; Social phobia
  • Preclinical Anxiety disorders

Most Recent Events

  • 08 Jan 2016 Phase II development is ongoing for Social phobia and Generalised anxiety disorder in USA
  • 08 Jan 2016 Preclinical development for Anxiety disorders is ongoing in USA (controlled release formulation)
  • 22 Jan 2009 Phase-II clinical trials in Generalised anxiety disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top